WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Construction In Progress : $1,926 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Construction In Progress?

WuXi Biologics (Cayman)'s quarterly construction in progress declined from Dec. 2022 ($2,286 Mil) to Jun. 2023 ($0 Mil) but then increased from Jun. 2023 ($0 Mil) to Dec. 2023 ($1,926 Mil).

WuXi Biologics (Cayman)'s annual construction in progress increased from Dec. 2021 ($1,707 Mil) to Dec. 2022 ($2,286 Mil) but then declined from Dec. 2022 ($2,286 Mil) to Dec. 2023 ($1,926 Mil).

WuXi Biologics (Cayman) Construction In Progress Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Construction In Progress Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

544.32

1,362.68

1,707.04

2,285.67

1,925.67

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Construction In Progress	Get a 7-Day Free Trial													1,707.04	-	2,285.67	-	1,925.67

WuXi Biologics (Cayman) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXIBF) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.